• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

冠状动脉疾病的风险因素(综述)

RISK-FACTORS OF CORONARY ARTERY DISEASE (REVIEW).

作者信息

Kantaria M, Buleishvili M, Kipiani Nina V, Ormotsadze G, Sanikidze T

机构信息

2Davit Aghmashenebeli University of Georgia; 3N. Kipshidze Central University Clinic; 4Georgian National University SEU, Tbilisi, Georgia.

1Tbilisi State Medical University; 3N. Kipshidze Central University Clinic; 4Georgian National University SEU, Tbilisi, Georgia.

出版信息

Georgian Med News. 2020 Feb(299):78-82.

PMID:32242850
Abstract

The treatment of coronary arteries disease (CAD) and the prevention of their complications, intervention on the coronary arteries is usually recommended. In this review, with the aim of improving the treatment outcomes of patients with CAD, requiring percutaneous coronary intervention and/or coronary artery bypass grafting,risk factors of developing coronary syndrome are discussed. Understanding the causes of the disturbance of coronary artery conduction will provide a new perspective for improving patient treatment outcomes. Revascularization cannot protect against future acute thrombotic events; for the successful treatment of CAD combining optimal revascularization strategies with long-term measures of risk reduction in lifestyle, often in combination with pharmacological measures, is needed. Numerous primary and secondary prevention trials have shown that management of modifiable risk factors (reduction in LDL-cholesterol level, decrease in blood pressure, discontinuation of smoking) reduces death rates, myocardial infarction, stroke, and other cardiovascular events, including the need for revascularization. Refined guidelines for the primary and secondary prevention of atherosclerosis account for modifiable and nonmodifiable, and other emerging risk factors of CAD.

摘要

对于冠状动脉疾病(CAD)的治疗及其并发症的预防,通常建议对冠状动脉进行干预。在本综述中,为了改善需要经皮冠状动脉介入治疗和/或冠状动脉旁路移植术的CAD患者的治疗效果,我们讨论了发生冠状动脉综合征的危险因素。了解冠状动脉传导障碍的原因将为改善患者治疗效果提供新的视角。血运重建无法预防未来的急性血栓事件;要成功治疗CAD,需要将最佳血运重建策略与长期的生活方式风险降低措施(通常与药物治疗措施相结合)相结合。众多一级和二级预防试验表明,控制可改变的危险因素(降低低密度脂蛋白胆固醇水平、降低血压、戒烟)可降低死亡率、心肌梗死、中风及其他心血管事件的发生率,包括血运重建的需求。针对动脉粥样硬化一级和二级预防的完善指南考虑了CAD的可改变和不可改变的危险因素以及其他新出现的危险因素。

相似文献

1
RISK-FACTORS OF CORONARY ARTERY DISEASE (REVIEW).冠状动脉疾病的风险因素(综述)
Georgian Med News. 2020 Feb(299):78-82.
2
Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease: A Meta-Analysis of Individual Patient Data.冠状动脉旁路移植术与药物洗脱支架置入术治疗左主干或多支冠状动脉疾病:一项个体患者数据的荟萃分析。
JACC Cardiovasc Interv. 2016 Dec 26;9(24):2481-2489. doi: 10.1016/j.jcin.2016.10.008.
3
Risk factor control for coronary artery disease secondary prevention in large randomized trials.大型随机试验中冠心病二级预防的危险因素控制。
J Am Coll Cardiol. 2013 Apr 16;61(15):1607-15. doi: 10.1016/j.jacc.2013.01.044.
4
B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial.B 型利钠肽评估在左主干冠状动脉疾病血运重建患者中的应用:来自 EXCEL 试验的分析。
Circulation. 2018 Jul 31;138(5):469-478. doi: 10.1161/CIRCULATIONAHA.118.033631.
5
Incidence, Characteristics, Predictors, and Outcomes of Repeat Revascularization After Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting: The SYNTAX Trial at 5 Years.经皮冠状动脉介入治疗和冠状动脉旁路移植术后重复血运重建的发生率、特征、预测因素和结果:SYNTAX 试验 5 年随访。
JACC Cardiovasc Interv. 2016 Dec 26;9(24):2493-2507. doi: 10.1016/j.jcin.2016.09.044.
6
Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization.全球冠状动脉血流储备与不良心血管事件相关,独立于管腔血管造影严重程度,并改变了早期血运重建的效果。
Circulation. 2015 Jan 6;131(1):19-27. doi: 10.1161/CIRCULATIONAHA.114.011939. Epub 2014 Nov 16.
7
API expert consensus document on management of ischemic heart disease.缺血性心脏病管理的API专家共识文件
J Assoc Physicians India. 2006 Jun;54:469-80.
8
Comparative determinants of 5-year cardiovascular event rates in patients with unprotected left main coronary artery disease.无保护左主干冠状动脉疾病患者5年心血管事件发生率的比较性决定因素
Coron Artery Dis. 2017 Aug;28(5):387-394. doi: 10.1097/MCA.0000000000000497.
9
Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis.经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗左主干狭窄患者的比较:系统评价和荟萃分析。
JAMA Cardiol. 2017 Oct 1;2(10):1079-1088. doi: 10.1001/jamacardio.2017.2895.
10
Ischemia change in stable coronary artery disease is an independent predictor of death and myocardial infarction.稳定型冠状动脉疾病中的缺血改变是死亡和心肌梗死的独立预测因子。
JACC Cardiovasc Imaging. 2012 Jul;5(7):715-24. doi: 10.1016/j.jcmg.2012.01.019.

引用本文的文献

1
Research progress in the management of vascular disease with cannabidiol: a review.大麻二酚治疗血管疾病的研究进展:综述。
J Cardiothorac Surg. 2024 Jan 3;19(1):6. doi: 10.1186/s13019-023-02476-y.
2
Heartwatch: an Irish cardiovascular secondary prevention programme in primary care, a secondary analysis of patient outcomes.《心监护:爱尔兰初级医疗中的心血管二级预防计划,对患者结局的二次分析》
BMJ Open. 2023 Jan 4;13(1):e063811. doi: 10.1136/bmjopen-2022-063811.
3
Disease burden and risk factors of ischemic heart disease in China during 1990-2019 based on the Global Burden of Disease 2019 report: A systematic analysis.
基于 2019 年全球疾病负担研究报告:系统分析 1990-2019 年中国缺血性心脏病的疾病负担和风险因素。
Front Public Health. 2022 Nov 3;10:973317. doi: 10.3389/fpubh.2022.973317. eCollection 2022.
4
Missense Variant rs28362680 in Reduces Risk of Coronary Heart Disease.rs28362680错义变异降低冠心病风险。
Pharmgenomics Pers Med. 2022 May 6;15:449-464. doi: 10.2147/PGPM.S353085. eCollection 2022.
5
Effect of cigarette smoking on coronary arteries and pattern and severity of coronary artery disease: a review.吸烟对冠状动脉的影响及冠状动脉疾病的类型和严重程度:综述。
J Int Med Res. 2021 Dec;49(12):3000605211059893. doi: 10.1177/03000605211059893.